
Large Molecule Drug Developer

High-end Ophthalmic Medical Device Developer

NOVACYTE
Series B1 Financing

NOVACYTE THERAPEUTICS was founded in October 2015. Over the years, it has focused on developing conjugate drugs for unmet clinical needs by utilizing original and highly differentiated innovative technology platforms. The company has a complete R&D team and has built multiple conjugate technology platforms with independent intellectual property rights. Innovative linker-payload combinations have demonstrated excellent clinical potential in non-clinical evaluations.
Qingyuan Kaiwu
Tens of Millions of Yuan in Pre-A+ Round Financing

BioGeometry
Pre-A Round Financing

BioGeometry focuses on building a generative AI protein design platform to empower the entire biomanufacturing field. Its core team is a pioneer in applying generative AI to molecular generation, having utilized diffusion models for 3D molecular structure generation as early as 2021. This was one of the first teams to apply diffusion generative models to 3D molecular structure generation, with the key paper GeoDiff being one of the top 50 most cited papers in the AI field in 2022.
TowardPi
$200 Million Series D Financing

TowardPi was founded in 2017, with its core technology originating from the transformation of scientific and technological achievements at Tsinghua University, and incubated by the Tsinghua Industrial Innovation Research Institute. TowardPi's product line includes ophthalmic OCT, surgical microscopes, ultra-wide-field fundus cameras, optical biometers, and more. Their products are sold in dozens of countries worldwide, with femtosecond laser and phacoemulsification/vitrectomy product lines currently under development.
TimeXi Bio
Tens of Millions of Angel + Round Financing

Shixi Bio is a nucleic acid drug research and development company that focuses on developing innovative drugs for indications with no effective conventional treatments through an RNA editing technology platform. The targeted indication areas include cardiovascular and cerebrovascular diseases, neurological disorders, respiratory conditions, anti-aging, and other fields with significant unmet clinical needs.
Evolution Healthcare
Tens of Millions of RMB in Angel Round Financing

Evolution Healthcare is a cross-species tumor gene therapy service provider established in 2023. It focuses on plant RDR1 protein-mediated miRNA repair therapy as its core technology, offering new solutions for clinical needs involving recurrent, refractory, and untreatable conditions. This therapy holds immense market potential and value, with the prospect of becoming the first broad-spectrum anti-tumor platform applicable to multiple cancer indications.
Shenji Changhua
Nearly 100 Million Pre-A Round Financing

Shenji Changhua, relying on over a decade of scientific research accumulation by Professor Yi-Chang Jia's team from the School of Medicine at Tsinghua University, has established platforms for novel gene knock-in animal disease models, such as fruit flies and mice, and a central nervous system adeno-associated virus (AAV) vector screening platform. It is committed to developing treatments for neurological diseases such as amyotrophic lateral sclerosis (ALS, commonly known as "Lou Gehrig's disease"), stroke, and Parkinson’s disease.
Microsynthesis
Over 300 Million Yuan in Series A Financing

MicroSynth Biotech began operations in 2022, focusing on technological innovation and industrialization in synthetic biology. The company provides bio-based raw materials and solutions to customers in pharmaceuticals, cosmetics, agriculture, food, feed, and materials industries through green production methods. Its current main products include sugar alcohols and rare sugars, natural pigments, and active molecules.
Heart of Molecules
Hundreds of Millions of Dollars in Series A Financing

MoleculeMind is a leading AI protein design platform company in China, founded by Jinbo Xu, a global pioneer in AI protein folding technology and a computational biologist. Currently, MoleculeMind has partnered with national-level life science laboratories. The company has developed "MoleculeOS," an AI large-molecule optimization and design platform with independent intellectual property rights. Using data-driven deep learning methods, it assists biotechnology experts in quickly identifying and generating the most suitable proteins, rapidly scaling laboratory research results for industrial applications.
Saiyun Bio
Tens of Millions of Angel Financing

Saiyun Bio is committed to the development of cutting-edge international delivery carrier technologies and related innovative drug therapies, aiming to provide a novel approach for precise drug delivery. The company has developed a class of natural delivery systems that, through rational modification, can directly deliver various types of payloads, such as functional proteins, into specific cells. This delivery system offers advantages such as high specificity in cell recognition, high compatibility and protection for payloads, and low production costs.
YiMing Bio
Nearly 200 Million Yuan in Financing

Yiming Biotech, established in 2015, is a research and production-oriented biotechnology company dedicated to the development and application of ATMPs technology, providing one-stop CDMO comprehensive solutions for innovative pharmaceutical enterprises. Notably, Yiming Biotech successfully settled into Zhongguancun Life Science Park in October 2024.
